Hematopoietic defects in HOXA9 ؊/؊ mice demonstrate a key role for this homeoprotein in blood cell development. Conversely, enforced HOXA9 expression is leukemogenic in mice, and HOXA9 is frequently activated in human acute myeloid leukemia (AML). Although HOXA9 is thought to function as a transcription factor, few downstream targets have been identified. We searched for early HOXA9 target genes by using a transient overexpression strategy in 3 hematopoietic cell lines (2 myeloid, 1 lymphoid). cDNA microarray analyses identified 220 genes whose expression was modulated at least 2-fold. Expression IntroductionHOX homeodomain proteins exert important effects during embryogenesis and blood cell development. [1][2][3] As a member of this large family, HOXA9 is expressed in normal human CD34 ϩ blood cells and is down-regulated during differentiation. HOXA9-deficient mice display a variety of myeloid and lymphoid defects. 4,5 HOXA9 overexpression in bone marrow cells induces marked stem cell expansion, and HOXA9 Ϫ/Ϫ hematopoietic stem cells appear to have a major proliferative defect 6 (H.J. L. et al, in preparation).Several studies have established a role for HOXA9 overexpression in myeloid leukemogenesis. Acute myeloid leukemia (AML) arising in leukemia-prone BXH2 mice shows frequent retroviral activation of HOXA9. 7 Retroviral overexpression of HOXA9 immortalizes murine marrow cells in vitro and readily leads to leukemic transformation in vivo. 8,9 HOXA9 is also important in human AML because this gene is activated in most patients with acute AML, and a t(7;11) chromosomal translocation resulting in a NUP98-HOXA9 gene fusion is found in some patients. 7,10 In a previous gene expression study in human leukemia, HOXA9 emerged as one of the top 20 genes that distinguished AML from acute lymphoid leukemia (ALL), and high levels of HOXA9 expression correlated with poor prognosis. 11,12 Thus, HOXA9 expression is part of the gene expression signature for AML and may also be a prognostic factor.Several HOX genes, including HOXA9, are direct targets of the mixed lineage leukemia gene (MLL), and leukemias associated with MLL translocations show uniform activation of HOXA9. [13][14][15][16] The ability of an MLL fusion gene to induce myeloid leukemia in murine marrow cells requires the presence of HOXA9, suggesting that HOXA9 is a mediator of the transforming effects of MLL fusion proteins. 17 Thus, altered HOXA9 gene expression may be a common pathway that unifies diverse initiating events in many myeloid leukemias. 18 Because HOXA9 exerts major biologic effects on normal and leukemic hematopoiesis, and because very little is known about the molecular pathways regulated by this homeoprotein, we completed a comprehensive gene expression profile of hematopoietic cells in which HOXA9 was transiently overexpressed. This study reveals that HOXA9 rapidly modulates the expression of a large number of genes that are implicated in normal hematopoiesis and in oncogenesis. Materials and methods Cell linesTetracycline (tet)-inducibl...

There is growing evidence for a role of HOX homeodomain proteins in normal hematopoiesis. Several HOX genes, including HOXA9 and HOXA10, are expressed in primitive hematopoietic cells, implying a role in early hematopoietic differentiation. To identify potential target genes of these two closely related transcription factors, human CD34 + umbilical cord blood cells were transduced with vectors expressing either HOXA9 or HOXA10 and analyzed with cDNA microarrays. Statistical analysis using significance analysis of microarrays revealed a common signature of several hundred genes, demonstrating that the transcriptomes of HOXA9 and HOXA10 largely overlap in this cellular context. Seven genes that were upregulated by both HOX proteins were validated by real-time reverse transcription polymerase chain reaction. 2005;23:644-655

While investigating the mechanism of action of the HOXA9 protein, we serendipitously identified Meis1 as a HOXA9 regulatory target. Since HOXA9 and MEIS1 play key developmental roles, are cooperating DNA binding proteins and leukemic oncoproteins, and are important for normal hematopoiesis, the regulation of Meis1 by its partner protein is of interest. Loss of Hoxa9 caused downregulation of the Meis1 mRNA and protein, while forced HOXA9 expression upregulated Meis1. Hoxa9 and Meis1 expression was correlated in hematopoietic progenitors and acute leukemias. Meis1 ؉/؊ Hoxa9 ؊/؊ deficient mice, generated to test HOXA9 regulation of endogenous Meis1, were small and had reduced bone marrow Meis1 mRNA and significant defects in fluorescence-activated cell sorting-enumerated monocytes, mature and pre/pro-B cells, and functional B-cell progenitors. These data indicate that HOXA9 modulates Meis1 during normal murine hematopoiesis. Chromatin immunoprecipitation analysis did not reveal direct binding of HOXA9 to Meis1 promoter/enhancer regions. However, Creb1 and Pknox1, whose protein products have previously been reported to induce Meis1, were shown to be direct targets of HOXA9. Loss of Hoxa9 resulted in a decrease in Creb1 and Pknox1 mRNA, and forced expression of CREB1 in Hoxa9 ؊/؊ bone marrow cells increased Meis1 mRNA almost as well as HOXA9, suggesting that CREB1 may mediate HOXA9 modulation of Meis1 expression.While the Hox homeobox genes are widely recognized as important developmental genes (26), we and others have shown that several Hox genes, and Hoxa9 in particular, are important for both normal hematopoiesis (27, 28) and leukemic transformation (25,29). While the Hoxa9 gene plays a role in embryonic development, much of the research on this gene has focused on its role as an oncogene that is often upregulated in acute myeloid leukemias (12,29). In an analysis of 6,817 genes, Hoxa9 was the most highly positively correlated with treatment failure in acute myeloid leukemia patients (18). Meis1 is a member of the TALE family of non-Hox homeobox genes, which was initially identified as a frequent viral integration site in myeloid leukemias arising in BXH2 mice (32). The Hoxa9 gene is also upregulated in many of the leukemias arising in the BXH2 animals (33). Hoxa9 is expressed in numerous tissues during development, including rib (8), limb (17), motor neuron progenitors (10), reproductive tract (9), and mammary gland (7). Hoxa9 is also expressed in normal adult BM (24, 43), and loss of Hoxa9 leads to multiple relatively mild defects in normal hematopoiesis (23,27,28). Retroviral expression studies have also shown that HOXA9 and MEIS1 are important for myeloid blood cell differentiation (3, 4). Despite the broad expression of Hoxa9 and other Hox genes, relatively little is known about how the HOX proteins function. An important advance was the discovery that many HOX proteins gain DNA binding specificity by forming complexes with the PBX (6, 31), MEIS1 (41), and PREP1 (2) proteins. Although HOXA9 is capable of bind...

K-Cl cotransport (COT), a ouabain-insensitive, Cl-dependent bidirectional K flux, is ubiquitously present in all cells, plays a major role in ion and volume homeostasis, and is activated by cell swelling and a variety of chemical interventions. Lithium modulates several cation transport pathways and inhibits phospholipid turnover in red blood cells (RBCs). Lithium also inhibits K-Cl COT by an unknown mechanism. To test the hypothesis whereby Li inhibits swelling-activated K-Cl COT by altering either its osmotic response, its regulation, or by competing with K for binding sites, low K (LK) sheep (S) RBCs were loaded with Li by Na/Li exchange or the cation ionophore nystatin. K-Cl COT was measured as the Cl-dependent, ouabain-insensitive K efflux or Rb influx. The results show that Li altered the cell morphology, and increased both cell volume and diameter. Internal (Li(i)) but not external (Li(o)) Li inhibited swelling-activated K-Cl COT by 85% with an apparent K(i) of approximately 7 mm. In Cl, Li(i) decreased K efflux at relative cell volumes between 0.9 and 1.2, and at external pHs between 7.2 and 7.4. Li(i) reduced the V(max) and increased the K(m) for K efflux in Cl. Furthermore, Li(i) increased the production of diacylglycerol in a bimodal fashion, without significant effects on the phosphatidylinositol concentration, and revealed the presence of a complete PI cycle in LK SRBCs. Finally, phorbol ester treatment and PD89059, an inhibitor of mitogen-activated protein kinase (ERK2) kinase, caused a time-dependent inhibition of K-Cl COT. Hence, Li(i) appears to inhibit K-Cl COT by acting at an allosteric site on the transporter or its putative regulators, and by modulation of the cellular phospholipid metabolism and a PKC-dependent regulatory pathway, causes an altered response of K-Cl COT to pH and volume.

The K+-Cl- cotransport (COT) regulatory pathways recently uncovered in our laboratory and their implication in disease state are reviewed. Three mechanisms of K+-Cl- COT regulation can be identified in vascular cells: (1) the Li+-sensitive pathway, (2) the platelet-derived growth factor (PDGF)-sensitive pathway and (3) the nitric oxide (NO)-dependent pathway. Ion fluxes, Western blotting, semi-quantitative RT-PCR, immunofluorescence and confocal microscopy were used. Li+, used in the treatment of manic depression, stimulates volume-sensitive K+-Cl- COT of low K+ sheep red blood cells at cellular concentrations <1 mM and inhibits at >3 mM, causes cell swelling, and appears to regulate K+-Cl- COT through a protein kinase C-dependent pathway. PDGF, a potent serum mitogen for vascular smooth muscle cells (VSMCs), regulates membrane transport and is involved in atherosclerosis. PDGF stimulates VSM K+-Cl- COT in a time- and concentration-dependent manner, both acutely and chronically, through the PDGF receptor. The acute effect occurs at the post-translational level whereas the chronic effect may involve regulation through gene expression. Regulation by PDGF involves the signalling molecules phosphoinositides 3-kinase and protein phosphatase-1. Finally, the NO/cGMP/protein kinase G pathway, involved in vasodilation and hence cardiovascular disease, regulates K+-Cl- COT in VSMCs at the mRNA expression and transport levels. A complex and diverse array of mechanisms and effectors regulate K+-Cl- COT and thus cell volume homeostasis, setting the stage for abnormalities at the genetic and/or regulatory level thus effecting or being affected by various pathological conditions.